Global Drug Discovery Services Market to Reach $61.1 Billion by 2030

NEW YORK, Feb. 8, 2023 /PRNewswire/ -- The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia's war on Ukraine will play out this year and the war's role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Read the full report: URL

Global Drug Discovery Services Market to Reach $61.1 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Drug Discovery Services estimated at US$42.9 Billion in the year 2022, is projected to reach a revised size of US$61.1 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2022-2030. Medicinal Chemistry Services, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$31.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biology Services segment is readjusted to a revised 4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $11.5 Billion, While China is Forecast to Grow at 8.2% CAGR

The Drug Discovery Services market in the U.S. is estimated at US$11.5 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$14.1 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.9% and 2.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$9.1 Billion by the year 2030.

Select Competitors (Total 33 Featured)

• Albany Molecular Research Inc.

• Charles River Laboratories International Inc.

• Domainex

• Eurofins Scientific SE

• Evotec A.G.

• GenScript Biotech Corporation

• Jubilant Biosys Ltd.

• Laboratory Corporation of America Holdings

• Pharmaceutical Product Development LLC

• Piramal Enterprises Ltd.

• Selvita S.A.

• Thermo Fisher Scientific Inc.

• WuXi AppTec

Read the full report: URL

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Impact of Covid-19 and a Looming Global Recession

Drug Discovery Services - Global Key Competitors Percentage

Market Share in 2022 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for

Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Drug

Discovery Services by Geographic Region - USA, Canada, Japan,

China, Europe, Asia-Pacific, Latin America, Middle East and

Africa Markets - Independent Analysis of Annual Sales in US$

Million for Years 2022 through 2030 and % CAGR

Table 2: World Historic Review for Drug Discovery Services by

Geographic Region - USA, Canada, Japan, China, Europe,

Asia-Pacific, Latin America, Middle East and Africa Markets -

Independent Analysis of Annual Sales in US$ Million for Years

2012 through 2021 and % CAGR

Table 3: World 18-Year Perspective for Drug Discovery Services

by Geographic Region - Percentage Breakdown of Value Sales for

USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,

Middle East and Africa Markets for Years 2012, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for

Medicinal Chemistry Services by Geographic Region - USA,

Canada, Japan, China, Europe, Asia-Pacific, Latin America,

Middle East and Africa Markets - Independent Analysis of Annual

Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Medicinal Chemistry Services

by Geographic Region - USA, Canada, Japan, China, Europe,

Asia-Pacific, Latin America, Middle East and Africa Markets -

Independent Analysis of Annual Sales in US$ Million for Years

2012 through 2021 and % CAGR

Table 6: World 18-Year Perspective for Medicinal Chemistry

Services by Geographic Region - Percentage Breakdown of Value

Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,

Latin America, Middle East and Africa for Years 2012, 2023 &

2030

Table 7: World Recent Past, Current & Future Analysis for

Biology Services by Geographic Region - USA, Canada, Japan,

China, Europe, Asia-Pacific, Latin America, Middle East and

Africa Markets - Independent Analysis of Annual Sales in US$

Million for Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for Biology Services by

Geographic Region - USA, Canada, Japan, China, Europe,

Asia-Pacific, Latin America, Middle East and Africa Markets -

Independent Analysis of Annual Sales in US$ Million for Years

2012 through 2021 and % CAGR

Table 9: World 18-Year Perspective for Biology Services by

Geographic Region - Percentage Breakdown of Value Sales for

USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,

Middle East and Africa for Years 2012, 2023 & 2030

Table 10: World Recent Past, Current & Future Analysis for Drug

Metabolism & Pharmacokinetics by Geographic Region - USA,

Canada, Japan, China, Europe, Asia-Pacific, Latin America,

Middle East and Africa Markets - Independent Analysis of Annual

Sales in US$ Million for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Drug Metabolism &

Pharmacokinetics by Geographic Region - USA, Canada, Japan,

China, Europe, Asia-Pacific, Latin America, Middle East and

Africa Markets - Independent Analysis of Annual Sales in US$

Million for Years 2012 through 2021 and % CAGR

Table 12: World 18-Year Perspective for Drug Metabolism &

Pharmacokinetics by Geographic Region - Percentage Breakdown of

Value Sales for USA, Canada, Japan, China, Europe,

Asia-Pacific, Latin America, Middle East and Africa for Years

2012, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for

Cardiovascular Diseases by Geographic Region - USA, Canada,

Japan, China, Europe, Asia-Pacific, Latin America, Middle East

and Africa Markets - Independent Analysis of Annual Sales in

US$ Million for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Cardiovascular Diseases by

Geographic Region - USA, Canada, Japan, China, Europe,

Asia-Pacific, Latin America, Middle East and Africa Markets -

Independent Analysis of Annual Sales in US$ Million for Years

2012 through 2021 and % CAGR

Table 15: World 18-Year Perspective for Cardiovascular Diseases

by Geographic Region - Percentage Breakdown of Value Sales for

USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,

Middle East and Africa for Years 2012, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for

Other Therapeutic Areas by Geographic Region - USA, Canada,

Japan, China, Europe, Asia-Pacific, Latin America, Middle East

and Africa Markets - Independent Analysis of Annual Sales in

US$ Million for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Other Therapeutic Areas by

Geographic Region - USA, Canada, Japan, China, Europe,

Asia-Pacific, Latin America, Middle East and Africa Markets -

Independent Analysis of Annual Sales in US$ Million for Years

2012 through 2021 and % CAGR

Table 18: The World 18-Year Perspective on Other Therapeutic Areas

By Geographic Region - Percentage breakdown of value sales

USA, Canada Japan, China Europe Asia-Pacific, Latin America

Middle East and Africa in 2012, 2023 and 2030

Table 19: World Recent Past and Future Analysis

Geographic Regions in Oncology - USA, Canada Japan, China

Europe, Asia-Pacific and Latin America. Middle East, Africa, Middle East, Africa.

Markets - Independent Analysis Of Annual Sales in US$ million

For the years 2022 to 2030, and % CAGR

Table 20: World Historic Review for Oncology, Geographic

Region - USA. Canada. Japan. China. Europe. Asia-Pacific. Latin.

America, Middle East, and Africa Markets – Independent Analysis

Yearly Sales in US$ Millions for the Years 2012-2021

CAGR %

Table 21: The World 18-Year Perspective on Oncology by Geographic

Region - Percentage breakdown of value sales for USA and Canada

Japan, China and Europe, Asia-Pacific. Latin America. Middle East.

Africa for the Years 2012, 2023, & 2030

Table 22: World Recent Past and Future Analysis

Neurology by Geographic Region – USA, Canada Japan, China

Europe, Asia-Pacific and Latin America. Middle East, Africa, Middle East, Africa.

Markets - Independent Analysis Of Annual Sales in US$ million

For the years 2022 to 2030, and % CAGR

Table 23: World Historic Review for Neurology, Geographic

Region - USA. Canada. Japan. China. Europe. Asia-Pacific. Latin.

America, Middle East, and Africa Markets – Independent Analysis

Yearly Sales in US$ Millions for the Years 2012-2021

CAGR %

Table 24: The World 18-Year Perspective on Neurology by Geographic

Region - Percentage breakdown of value sales for USA and Canada

Japan, China and Europe, Asia-Pacific. Latin America. Middle East.

Africa for the Years 2012, 2023, & 2030

Table 25: World Recent Past and Future Analysis

The Geographic Regions of Infectious and Immune System Diseases - USA

Canada, Japan and China, Europe, Asia-Pacific, Latin America

Markets in the Middle East and Africa - Independent Analysis of Annual

Year 2022 to 2030: Sales in US$ million and % CAGR

Table 26: World Historic Review for Infectious & Immune System

Diseases by Geographic Region – USA, Canada Japan, China

Europe, Asia-Pacific and Latin America. Middle East, Africa, Middle East, Africa.

Markets - Independent Analysis Of Annual Sales in US$ million

For Years 2012-2021, and % CAGR

Table 27: The World 18-Year Perspective on Infectious Diseases & Immune

System Diseases by Geographic Region: Percentage Breakdown

USA, Canada Japan, China, Europe Value Sales

Asia-Pacific, Latin America and the Middle East for years

2012, 2023 & 2030

Table 28: World Recent Past and Future Analysis

Digestive System Diseases By Geographic Region - USA, Canada

Japan, China and Europe, Asia-Pacific. Latin America. Middle East.

Africa Markets - Independent Analysis Of Annual Sales

US$ million for the Years 2022 to 2030, and % CAGR

Table 29: World Historic Review for Digestive System Diseases

By Geographic Region - USA. Canada. Japan. China. Europe.

Asia-Pacific, Latin America and Middle East Markets

Independent Analysis of Annual Sales in US$ million for Years

2012-2021 and % CAGR

Table 30: World 18-Year Perspective for Digestive System

Diseases by Geographic Region: Percentage Breakdown of Value

USA, Canada Japan, China Europe, Asia-Pacific

Latin America, Middle East, and Africa for the Years 2012-2023

2030

Table 31: World Recent Past and Future Analysis

Small Molecules, by Geographic Region - USA Canada Japan

China, Europe and the Middle East.

Africa Markets - Independent Analysis Of Annual Sales in US$

Millions for the Years 2022 to 2030 and % CAGR

Table 32: World Historic Review for Small Molecules

Geographic Region - USA. Canada. Japan. China. Europe.

Asia-Pacific, Latin America and Middle East Markets

Independent Analysis of Annual Sales in US$ million for Years

2012-2021 and % CAGR

Table 33: The World 18-Year Perspective on Small Molecules

Geographic Region - Percentage breakdown of value sales

USA, Canada Japan, China Europe Asia-Pacific, Latin America

Middle East and Africa in 2012, 2023 and 2030

Table 34: World Recent Past and Future Analysis

Biologics by Geographic Region: USA, Canada Japan, China

Europe, Asia-Pacific and Latin America. Middle East, Africa, Middle East, Africa.

Markets - Independent Analysis Of Annual Sales in US$ million

For the years 2022 to 2030, and % CAGR

Table 35: World Historic Review of Biologics by Geographic

Region - USA. Canada. Japan. China. Europe. Asia-Pacific. Latin.

America, Middle East, and Africa Markets – Independent Analysis

Yearly Sales in US$ Millions for the Years 2012-2021

CAGR %

Table 36: World 18 Year Perspective for Biologics, Geographic

Region - Percentage breakdown of value sales for USA and Canada

Japan, China and Europe, Asia-Pacific. Latin America. Middle East.

Africa for the Years 2012, 2023, & 2030

Table 37: World Drug Discovery Services Market Analysis

Year 2012 to 2030: Annual Sales in US$ million

III. MARKET ANALYSIS

UNITED STATES

Drug Discovery Services Market Presence Strong/Active/Niche

Trivial – Key Competitors in America for 2023 (E).

Table 38: USA Past, Present, and Future Analysis of Drugs

Discovery Services by Type – Medicinal Chemistry Services

Biology Services and Drug Metabolism & Pharmacokinetics –

Independent Analysis of Annual Sales in US$ million for the

Year 2022 to 2030 and % CAGR

Table 39: USA Historic Review for Drug Discovery Services

Type - Medicinal Chemistry Services and Biology Services and Drug

Markets for Metabolism & Pharmacokinetics - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 40: USA 18 Year Perspective for Drug Discovery Services

By Type - Percentage breakdown of value sales for medicinal

Services in Chemistry, Biology and Drug Metabolism

Pharmacokinetics in the Years 2012-2023 and 2030

Table 41: USA Past, Present, and Future Analysis of Drugs

Discovery Services by Therapeutic Zone - Cardiovascular

Diseases, other therapeutic areas, Oncology and Neurology

Digestive System and Infectious Diseases

Diseases - Independent Analysis on Annual Sales in US$ Million

For the years 2022 to 2030, and % CAGR

Table 42: USA Historic Review for Drug Discovery Services

Therapeutic Area - Cardiovascular Diseases and Other Therapeutic

The following areas are covered: Neurology, Oncology and Infectious & Infectious System Diseases

Markets for Digestive System Diseases and Digestive Systems Diseases - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 43: USA 18 Year Perspective for Drug Discovery Services

By Therapeutic Area - Percentage breakdown of value sales

Cardiovascular Diseases, Other Therapeutic Areas and Oncology

Neurology, Infectious and Immune System Diseases, and Digestive Disorders

System Diseases in 2012, 2023 and 2030

Table 44: USA Past, Present, and Future Analysis of Drugs

Discovery Services by Drug Type: Small Molecules and Biologics

Independent Analysis of Annual Sales in US$ million for the

Year 2022 to 2030 and % CAGR

Table 45: USA Historic Review for Drug Discovery Services

Type of Drug - Small Molecules Markets for Biologics Markets – Independent

Analyse of annual sales in US$ million for the years 2012 to 2012.

2021 and % CAGR

Table 46: USA 18 Year Perspective for Drug Discovery Services

By Drug Type - Percentage breakdown of Small Value Sales

For the years 2012, 2023 and 2030, Molecules & Biologics

CANADA

Table 47: Canada Recent Past, Current & Future Analysis for

Drug Discovery Services by Type – Medicinal Chemistry Services

Biology Services and Drug Metabolism & Pharmacokinetics –

Independent Analysis of Annual Sales in US$ million for the

Year 2022 to 2030 and % CAGR

Table 48: Canada Historic Review of Drug Discovery Services

Type - Medicinal Chemistry Services and Biology Services and Drug

Markets for Metabolism & Pharmacokinetics - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 49: Canada's 18-Year Perspective on Drug Discovery

Services by Type - Percentage breakdown of Value Sales

Medicinal Chemistry Services, Biology Services and Drug

Metabolism & Pharmacokinetics in the Years 2012-2023 & 2030

Table 50: Canada Recent Past, Current & Future Analysis for

Drug Discovery Services by Therapeutic Zone - Cardiovascular

Diseases, other therapeutic areas, Oncology and Neurology

Digestive System and Infectious Diseases

Diseases - Independent Analysis on Annual Sales in US$ Million

For the years 2022 to 2030, and % CAGR

Table 51: Canada Historic Review for Drug Discovery Services

Therapeutic Area - Cardiovascular Diseases and Other Therapeutic

The following areas are covered: Neurology, Oncology and Infectious & Infectious System Diseases

Markets for Digestive System Diseases and Digestive Systems Diseases - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 52: Canada's 18-Year Perspective on Drug Discovery

Services by Therapeutic Area – Percentage Breakdown Value

Cardiovascular Diseases and Other Therapeutic Areas:

Oncology, Neurology and Infectious & Immune Diseases

Digestive System Diseases in 2012, 2023 and 2030

Table 53: Canada Recent Past, Current & Future Analysis for

Drug Discovery Services by Drug Type Small Molecules

Biologics - Independent Analysis Of Annual Sales in US$ Million

For the years 2022 to 2030, and % CAGR

Table 54: Canada Historic Review for Drug Discovery Services

Drug Type - Small Molecules Markets for Biologics Markets – Independent

Analyse of annual sales in US$ million for the years 2012 to 2012.

2021 and % CAGR

Table 55: Canada's 18-Year Perspective on Drug Discovery

Services by Drug Type – Percentage Breakdown Value Sales

Small Molecules & Biologics for 2012, 2023, and 2030

JAPAN

Drug Discovery Services Market Presence Strong/Active/Niche

Trivial – Key Competitors in Japan 2023 (E).

Table 56: Japan's Past, Present, and Future Analysis of Drugs

Discovery Services by Type – Medicinal Chemistry Services

Biology Services and Drug Metabolism & Pharmacokinetics –

Independent Analysis of Annual Sales in US$ million for the

Year 2022 to 2030 and % CAGR

Table 57: Japan Historic Review for Drug Discovery Services

Type - Medicinal Chemistry Services and Biology Services and Drug

Markets for Metabolism & Pharmacokinetics - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 58: Japan's 18-Year Perspective on Drug Discovery Services

By Type - Percentage breakdown of value sales for medicinal

Services in Chemistry, Biology and Drug Metabolism

Pharmacokinetics in the Years 2012-2023 and 2030

Table 59: Japan's Past, Present, and Future Analysis of Drugs

Discovery Services by Therapeutic Zone - Cardiovascular

Diseases, other therapeutic areas, Oncology and Neurology

Digestive System and Infectious Diseases

Diseases - Independent Analysis on Annual Sales in US$ Million

For the years 2022 to 2030, and % CAGR

Table 60: Japan Historic Review for Drug Discovery Services

Therapeutic Area - Cardiovascular Diseases and Other Therapeutic

The following areas are covered: Neurology, Oncology and Infectious & Infectious System Diseases

Markets for Digestive System Diseases and Digestive Systems Diseases - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 61: Japan's 18-Year Perspective on Drug Discovery Services

By Therapeutic Area - Percentage breakdown of value sales

Cardiovascular Diseases, Other Therapeutic Areas and Oncology

Neurology, Infectious and Immune System Diseases, and Digestive Disorders

System Diseases in 2012, 2023 and 2030

Table 62: Japan's Past, Present, and Future Analysis of Drugs

Discovery Services by Drug Type: Small Molecules and Biologics

Independent Analysis of Annual Sales in US$ million for the

Year 2022 to 2030 and % CAGR

Table 63: Japan Historic Review for Drug Discovery Services

Drug Type - Small Molecules Markets for Biologics Markets – Independent

Analyse of annual sales in US$ million for the years 2012 to 2012.

2021 and % CAGR

Table 64: Japan's 18-Year Perspective on Drug Discovery Services

By Drug Type - Percentage breakdown of Small Value Sales

For the years 2012, 2023 and 2030, Molecules & Biologics

CHINA

Drug Discovery Services Market Presence Strong/Active/Niche

Trivial – Key Competitors in China 2023 (E).

Table 65: China's Recent Past, Present & Future Analysis of Drugs

Discovery Services by Type – Medicinal Chemistry Services

Biology Services and Drug Metabolism & Pharmacokinetics –

Independent Analysis of Annual Sales in US$ million for the

Year 2022 to 2030 and % CAGR

Table 66: China Historic Review for Drug Discovery Services

Type - Medicinal Chemistry Services and Biology Services and Drug

Markets for Metabolism & Pharmacokinetics - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 67: China's 18-Year Perspective on Drug Discovery Services

By Type - Percentage breakdown of value sales for medicinal

Services in Chemistry, Biology and Drug Metabolism

Pharmacokinetics in the Years 2012-2023 and 2030

Table 68: China's Recent Past, Present & Future Analysis of Drugs

Discovery Services by Therapeutic Zone - Cardiovascular

Diseases, other therapeutic areas, Oncology and Neurology

Digestive System and Infectious Diseases

Diseases - Independent Analysis on Annual Sales in US$ Million

For the years 2022 to 2030, and % CAGR

Table 69: China Historic Review for Drug Discovery Services

Therapeutic Area - Cardiovascular Diseases and Other Therapeutic

The following areas are covered: Neurology, Oncology and Infectious & Infectious System Diseases

Markets for Digestive System Diseases and Digestive Systems Diseases - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 70: China's 18-Year Perspective on Drug Discovery Services

By Therapeutic Area - Percentage breakdown of value sales

Cardiovascular Diseases, Other Therapeutic Areas and Oncology

Neurology, Infectious and Immune System Diseases and Digestive Disorders

System Diseases in 2012, 2023 and 2030

Table 71: China's Recent Past, Present & Future Analysis of Drugs

Discovery Services by Drug Type: Small Molecules and Biologics

Independent Analysis of Annual Sales in US$ million for the

Year 2022 to 2030 and % CAGR

Table 72: China Historic Review of Drug Discovery Services

Drug Type - Small Molecules Markets for Biologics Markets – Independent

Analyse of annual sales in US$ million for the years 2012 to 2012.

2021 and % CAGR

Table 73: China's 18-Year Perspective on Drug Discovery Services

By Drug Type - Percentage breakdown of Small Value Sales

For the years 2012, 2023 and 2030, Molecules & Biologics

EUROPE

Drug Discovery Services Market Presence Strong/Active/Niche/

Trivial – Key Competitors in Europe 2023 (E).

Table 74: Europe's Recent Past, Present, and Future Analysis

Drug Discovery Services by Geographic Regions - France, Germany

Italy, UK Spain Russia, Russia, and Rest of Europe Markets

Independent Analysis of Annual Sales in US$ million for Years

2022-2030 and % CAGR

Table 75: Europe Historic Review for Drug Discovery Services

Geographic Region - France and Germany, Italy, UK, Spain and Russia

Markets in Europe and Rest of Europe - Independent Analysis of Annual

Year 2012-2021: Sales in US$ Million and % CAGR

Table 76: Europe 18-Year Perspective for Drug Discovery

Services by Geographic Region – Percentage Breakdown Value

France, Germany and Russia sales

Europe Markets for Years 2012-2023 & 2030

Table 77: Europe's Recent Past, Present, and Future Analysis

Drug Discovery Services by Type – Medicinal Chemistry Services

Biology Services and Drug Metabolism & Pharmacokinetics –

Independent Analysis of Annual Sales in US$ million for the

Year 2022 to 2030 and % CAGR

Table 78: Europe Historic Review for Drug Discovery Services

Type - Medicinal Chemistry Services and Biology Services and Drug

Markets for Metabolism & Pharmacokinetics - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 79: Europe 18-Year Perspective for Drug Discovery

Services by Type - Percentage breakdown of Value Sales

Medicinal Chemistry Services, Biology Services and Drug

Metabolism & Pharmacokinetics in the Years 2012-2023 & 2030

Table 80: Europe's Recent Past, Present, and Future Analysis

Drug Discovery Services by Therapeutic Zone - Cardiovascular

Diseases, other therapeutic areas, Oncology and Neurology

Digestive System and Infectious Diseases

Diseases - Independent Analysis on Annual Sales in US$ Million

For the years 2022 to 2030, and % CAGR

Table 81: Europe Historic Review for Drug Discovery Services

Therapeutic Area - Cardiovascular Diseases and Other Therapeutic

The following areas are covered: Neurology, Oncology and Infectious & Infectious System Diseases

Markets for Digestive System Diseases and Digestive Systems Diseases - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 82: Europe 18-Year Perspective for Drug Discovery

Services by Therapeutic Area – Percentage Breakdown Value

Cardiovascular Diseases and Other Therapeutic Areas:

Neurology, Oncology, Infectious and Immune System Diseases, Neurology

Digestive System Diseases in 2012, 2023 and 2030

Table 83: Europe's Recent Past, Present, and Future Analysis

Drug Discovery Services by Drug Type Small Molecules

Biologics - Independent Analysis Of Annual Sales in US$ Million

For the years 2022 to 2030, and % CAGR

Table 84: Europe Historic Review for Drug Discovery Services

Type of Drug - Small Molecules Markets for Biologics Markets – Independent

Analyse of annual sales in US$ million for the years 2012 to 2012.

2021 and % CAGR

Table 85: Europe 18-Year Perspective for Drug Discovery

Services by Drug Type – Percentage Breakdown Value Sales

Small Molecules & Biologics for 2012, 2023, and 2030

FRANCE

Drug Discovery Services Market Presence Strong/Active/Niche

Trivial – Key Competitors in France 2023 (E).

Table 86: France Past, Present, and Future Analysis

Drug Discovery Services by Type – Medicinal Chemistry Services

Biology Services and Drug Metabolism & Pharmacokinetics –

Independent Analysis of Annual Sales in US$ million for the

Year 2022 to 2030 and % CAGR

Table 87: France Historic Review for Drug Discovery Services

Type - Medicinal Chemistry Services and Biology Services and Drug

Markets for Metabolism & Pharmacokinetics - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 88: France's 18-Year Perspective on Drug Discovery

Services by Type - Percentage breakdown of Value Sales

Medicinal Chemistry Services, Biology Services and Drug

Metabolism & Pharmacokinetics in the Years 2012-2023 & 2030

Table 89: France Past, Present, and Future Analysis

Drug Discovery Services by Therapeutic Zone - Cardiovascular

Diseases, other therapeutic areas, Oncology and Neurology

Digestive System and Infectious Diseases

Diseases - Independent Analysis on Annual Sales in US$ Million

For the years 2022 to 2030, and % CAGR

Table 90: France Historic Review for Drug Discovery Services

Therapeutic Area - Cardiovascular Diseases and Other Therapeutic

The following areas are covered: Neurology, Oncology and Infectious & Infectious System Diseases

Markets for Digestive System Diseases and Digestive Systems Diseases - Independent Analysis

Annual Sales in US$ Millions for Years 2012-2021 and %

CAGR

Table 91: France's 18-Year Perspective on Drug Discovery

Services by Therapeutic Area – Percentage Breakdown Value

Cardiovascular Diseases and Other Therapeutic Areas:

Neurology, Oncology, Infectious and Immune System Diseases, and

Digestive System Diseases in 2012, 2023 and 2030

Table 92: France Past, Present, and Future Analysis

Drug Discovery Services by Drug Type